Advertisement

Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?

  • Hamish CG Prosser
  • Cynthia Gregory
  • Dagmara Hering
  • Graham S Hillis
  • Greg Perry
  • Johan Rosman
  • Carl Schultz
  • Mark Thomas
  • Gerald F Watts
  • Markus P Schlaich
Resistant Hypertension (E Pimenta, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Resistant Hypertension

Abstract

Resistant hypertension (RH) is defined as blood pressure (BP) that remains above target levels despite adherence to at least three different antihypertensive medications, typically including a diuretic. Epidemiological studies estimate that RH is increasing in prevalence, and is associated with detrimental health outcomes. The pathophysiology underlying RH is complex, involving multiple, overlapping contributors including activation of the renin-angiotensin aldosterone system and the sympathetic nervous system, volume overload, endothelial dysfunction, behavioural and lifestyle factors. Hypertension guidelines currently recommend specific pharmacotherapy for 1st, 2nd and 3rd-line treatment, however no specific fourth-line pharmacotherapy is provided for those with RH. Rather, five different antihypertensive drug classes are generally suggested as possible alternatives, including: mineralocorticoid receptor antagonists, α1-adrenergic antagonists, α2-adrenergic agonists, β-blockers, and peripheral vasodilators. Each of these drug classes vary in their efficacy, tolerability and safety profile. This review summarises the available data on each of these drug classes as a potential fourth-line drug and reveals a lack of robust clinical evidence for preferred use of most of these classes in the setting of RH. Moreover, there is a lack of direct comparative trials that could assist in identifying a preferred fourth-line pharmacologic approach and in providing evidence for hypertensive guidelines for adequate treatment of RH.

Keywords

Resistant hypertension Pharmacotherapy Fourth-line therapy Antihypertensive medications 

Notes

Compliance with Ethics Standards

Conflict of Interest

Drs. Prosser, Gregory, Hering, Hillis, Perry, Rosman, Schultz, Thomas, Watts, and Schlaich declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510–26.PubMedCrossRefGoogle Scholar
  2. 2.
    Black H, Elliott W, Grandits G, Grambsch P, Lucente T, White W, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073–82.PubMedCrossRefGoogle Scholar
  3. 3.
    Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4(6):393–404.CrossRefGoogle Scholar
  4. 4.•
    Jamerson K, Weber M, Bakris G, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–28. This randomized controlled trial demonstrated the superiority of an ACEI plus CCB combination compared with and ACEI plus diuretic combination. PubMedCrossRefGoogle Scholar
  5. 5.
    Pepine C, Handberg E, Cooper-DeHoff R, Marks R, Kowey P, Messerli F, et al. A calcium antagonist vs. a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–16.PubMedCrossRefGoogle Scholar
  6. 6.
    Roberie DR, Elliott WJ. What is the prevalence of resistant hypertension in the United States? Curr Opin Cardiol. 2012;27(4):386–91.PubMedCrossRefGoogle Scholar
  7. 7.
    Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57(6):1076–80.PubMedCrossRefGoogle Scholar
  8. 8.
    Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303(20):2043–50.PubMedCrossRefGoogle Scholar
  9. 9.
    Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046–58.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    • de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898–902. This study used ambulatory BP assessment to determine the prevalence of true resistant hypertension in a hypertensive populatin. PubMedCrossRefGoogle Scholar
  11. 11.
    Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens. 2005;23(11):2101–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114–7.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Lawes CM, Vander Hoorn S, Rodgers A. International Society of H. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective SC. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.PubMedCrossRefGoogle Scholar
  15. 15.
    Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015;88(3):622–32.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    • Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–42. This study provides evidence for a substantially increased CV risk in patienst with resistant hypertension. PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Grassi G, Ram VS. Evidence for a critical role of the sympathetic nervous system in hypertension. Journal of the American Society of Hypertension: J Am Soc Hyp. 2016; doi: 10.1016/j.jash.2016.02.015.Google Scholar
  18. 18.
    Grassi G, Seravalle G, Brambilla G, Pini C, Alimento M, Facchetti R, et al. Marked sympathetic activation and baroreflex dysfunction in true resistant hypertension. Int J Cardiol. 2014;177(3):1020–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Oliva RV, Bakris GL. Sympathetic activation in resistant hypertension: theory and therapy. Sem Nephrol. 2014;34(5):550–9.CrossRefGoogle Scholar
  20. 20.
    Egan BM, Li J. Role of aldosterone blockade in resistant hypertension. Sem Nephrol. 2014;34(3):273–84.CrossRefGoogle Scholar
  21. 21.
    Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40(6):892–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004;109(23):2857–61.PubMedCrossRefGoogle Scholar
  23. 23.
    Brown NJ. Aldosterone and end-organ damage. Curr Opinion Nephrol Hyp. 2005;14(3):235–41.CrossRefGoogle Scholar
  24. 24.
    Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108(5):560–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009;20(5):933–9.PubMedCrossRefGoogle Scholar
  26. 26.
    El Rouby N, Cooper-DeHoff RM. Genetics of resistant hypertension: a novel pharmacogenomics phenotype. Curr Hyp Rep. 2015;17(9):583.Google Scholar
  27. 27.
    Sarafidis PA, Bakris GL. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens. 2008;10(2):130–9.CrossRefGoogle Scholar
  28. 28.
    Graves JW, Bloomfield RL, Buckalew Jr VM. Plasma volume in resistant hypertension: guide to pathophysiology and therapy. Am J Med Sci. 1989;298(6):361–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Townsend RR. Pathogenesis of drug-resistant hypertension. Sem Nephrol. 2014;34(5):506–13.CrossRefGoogle Scholar
  30. 30.
    DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients with obesity. Nature Rev Endocrinol. 2014;10(6):364–76.CrossRefGoogle Scholar
  31. 31.
    Rao A, Pandya V, Whaley-Connell A. Obesity and insulin resistance in resistant hypertension: implications for the kidney. Adv Chronic Kidney Dis. 2015;22(3):211–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutierrez OM, Irvin MR, et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013;8(9):1583–90.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Converse Jr RL, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327(27):1912–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. T N Engl J Med. 1999;340(17):1321–8.CrossRefGoogle Scholar
  35. 35.
    Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007;131(2):453–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001;19(12):2271–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Walia HK, Li H, Rueschman M, Bhatt DL, Patel SR, Quan SF, et al. Association of severe obstructive sleep apnea and elevated blood pressure despite antihypertensive medication use. J Clin Sleep Med. 2014;10(8):835–43.PubMedPubMedCentralGoogle Scholar
  38. 38.
    Grassi G, Facchini A, Trevano FQ, Dell’Oro R, Arenare F, Tana F, et al. Obstructive sleep apnea-dependent and -independent adrenergic activation in obesity. Hypertension. 2005;46(2):321–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Calhoun DA, Nishizaka MK, Zaman MA, Harding SM. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest. 2004;125(1):112–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Somers VK, Dyken ME, Clary MP, Abboud FM. Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest. 1995;96(4):1897–904.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Gaddam K, Pimenta E, Thomas SJ, Cofield SS, Oparil S, Harding SM, et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Hum Hypertens. 2010;24(8):532–7.PubMedCrossRefGoogle Scholar
  42. 42.
    James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20.PubMedCrossRefGoogle Scholar
  43. 43.
    Krause T, Lovibond K, Caulfield M, McCormack T, Williams B, Guideline DG. Management of hypertension: summary of NICE guidance. BMJ. 2011;343:d4891.PubMedCrossRefGoogle Scholar
  44. 44.
    Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. 2013 ESH/ESC practice guidelines for the management of arterial hypertension. Blood Press. 2014;23(1):3–16.PubMedCrossRefGoogle Scholar
  45. 45.
    Stern RH. The new hypertension guidelines. J Clin Hypertens. 2013;15(10):748–51.Google Scholar
  46. 46.
    Investigators O, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59.CrossRefGoogle Scholar
  47. 47.
    Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens. 2014;16(1):14–26.CrossRefGoogle Scholar
  48. 48.
    Judd EK, Calhoun DA, Warnock DG. Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels. Sem Nephrol. 2014;34(5):532–9.CrossRefGoogle Scholar
  49. 49.
    Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839–45.PubMedCrossRefGoogle Scholar
  50. 50.
    de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55(1):147–52.PubMedCrossRefGoogle Scholar
  51. 51.
    Vaclavik J, Sedlak R, Jarkovsky J, Kocianova E, Taborsky M. Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT). Medicine. 2014;93(27):e162.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57(6):1069–75.PubMedCrossRefGoogle Scholar
  53. 53.
    Ni X, Zhang J, Zhang P, Wu F, Xia M, Ying G, et al. Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study. J Clin Hypertens. 2014;16(9):658–63.CrossRefGoogle Scholar
  54. 54.
    Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013;31(10):2094–102.PubMedCrossRefGoogle Scholar
  55. 55.
    Dahal K, Kunwar S, Rijal J, Alqatahni F, Panta R, Ishak N, et al. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies. Am J Hypertens. 2015;28(11):1376–85.PubMedCrossRefGoogle Scholar
  56. 56.
    Douma S, Petidis K, Doumas M, Papaefthimiou P, Triantafyllou A, Kartali N, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008;371(9628):1921–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Slim HB, Black HR, Thompson PD. Older blood pressure medications-do they still have a place? Am J Cardiol. 2011;108(2):308–16.PubMedCrossRefGoogle Scholar
  58. 58.
    • Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–68. This study provides most robust evidence to date to indicate that spironolactone may be considered preferred 4 th line terapy for resistant hypertension PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Verdalles U, Garcia de Vinuesa S, Goicoechea M, Macias N, Santos A, Perez de Jose A, et al. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy? Nephrology. 2015;20(8):567–71.PubMedCrossRefGoogle Scholar
  60. 60.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med. 1999;341(10):709–17.PubMedCrossRefGoogle Scholar
  61. 61.
    • Azizi M, Perdrix L, Bobrie G, Frank M, Chatellier G, Menard J, et al. Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. J Hypertens. 2014;32(10):2038–44. This study compares various pharmacologic approaches as add-on thearpy in resistant hypertension. PubMedCrossRefGoogle Scholar
  62. 62.
    Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension. 2010;55(5):1137–42.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Montalescot G, Pitt B, Lopez de Sa E, Hamm CW, Flather M, Verheugt F, et al. Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The randomized double-blind reminder study. Eur Heart J. 2014;35(34):2295–302.PubMedCrossRefGoogle Scholar
  64. 64.
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309–21.PubMedCrossRefGoogle Scholar
  65. 65.
    Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009;30(5):418–24.PubMedCrossRefGoogle Scholar
  66. 66.
    Oxlund CS, Buhl KB, Jacobsen IA, Hansen MR, Gram J, Henriksen JE, et al. Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension. J Am Soc Hypertens. 2014;8(12):872–81.PubMedCrossRefGoogle Scholar
  67. 67.
    Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22(11):2217–26.PubMedCrossRefGoogle Scholar
  68. 68.
    Giugliano D, Acampora R, Marfella R, La Marca C, Marfella M, Nappo F, et al. Hemodynamic and metabolic effects of transdermal clonidine in patients with hypertension and non-insulin-dependent diabetes mellitus. Am J Hypertens. 1998;11(2):184–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Houston MC, Burger C, Hays JT, Nadeau J, Swift L, Bradley CA, et al. The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension. Am Heart J. 1990;120(1):172–9.PubMedCrossRefGoogle Scholar
  70. 70.
    McMahon FG, Jain AK, Vargas R, Fillingim J. A double-blind comparison of transdermal clonidine and oral captopril in essential hypertension. Clin Ther. 1990;12(2):88–100.PubMedGoogle Scholar
  71. 71.
    Schmidt GR, Schuna AA, Goodfriend TL. Transdermal clonidine compared with hydrochlorothiazide as monotherapy in elderly hypertensive males. J Clin Pharmacol. 1989;29(2):133–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Garrett BN, Kaplan NM. Clonidine in the treatment of hypertension. J Cardiovasc Pharmacol. 1980;2(Suppl 1):S61–71.PubMedCrossRefGoogle Scholar
  73. 73.
    Velasco M, Andrews-Figueroa P, Ramirez A, Morillo J, Urbina-Quintana A, Aliendres R, et al. Systemic and cardiac hemodynamic interactions between clonidine and minoxidil. Clin Pharmacol Ther. 1981;30(2):158–63.PubMedCrossRefGoogle Scholar
  74. 74.
    Sermswan A, Archawarak N. Methyldopa supplement for resistant essential hypertension: a prospective randomized placebo control crossover study. J Med Assoc Thail. 2003;86(12):1156–61.Google Scholar
  75. 75.
    Investigators R, Krieger EM, Drager LF, Giorgi DM, Krieger JE, Pereira AC, et al. Resistant hypertension optimal treatment trial: a randomized controlled trial. Clin Cardiol. 2014;37(1):1–6.CrossRefGoogle Scholar
  76. 76.
    Komanski CB, Rauck RL, North JM, Hong KS, D’Angelo R, Hildebrand KR. Intrathecal clonidine via lumbar puncture decreases blood pressure in patients with poorly controlled hypertension. Neuromodulation. 2015;18(6):499–507.PubMedCrossRefGoogle Scholar
  77. 77.
    Prichard BN, Graham BR. Effective antihypertensive therapy: blood pressure control with moxonidine. J Cardiovasc Pharmacol. 1996;27(Suppl 3):S38–48.PubMedCrossRefGoogle Scholar
  78. 78.
    Chazova I, Almazov VA, Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabetes Obes Metab. 2006;8(4):456–65.PubMedCrossRefGoogle Scholar
  79. 79.
    Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens. 1999;17(3):S29–35.Google Scholar
  80. 80.
    Fenton C, Keating GM, Lyseng-Williamson KA. Moxonidine: a review of its use in essential hypertension. Drugs. 2006;66(4):477–96.PubMedCrossRefGoogle Scholar
  81. 81.
    Ollivier JP, Christen MO. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience. J Cardiovasc Pharmacol. 1994;24(Suppl 1):S39–48.PubMedCrossRefGoogle Scholar
  82. 82.
    Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Failure. 2003;5(5):659–67.CrossRefGoogle Scholar
  83. 83.
    Martin U, Hill CDOM. Use of moxonidine in elderly patients with resistant hypertension. J Clin Pharm Ther. 2005;30(5):433–7.PubMedCrossRefGoogle Scholar
  84. 84.
    Schlaich MP, Lambert E, Kaye DM, Krozowski Z, Campbell DJ, Lambert G, et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and Angiotensin neuromodulation. Hypertension. 2004;43(2):169–75.PubMedCrossRefGoogle Scholar
  85. 85.
    Grimm Jr RH. Alpha 1-antagonists in the treatment of hypertension. Hypertension. 1989;13(5 Suppl):I131–6.PubMedCrossRefGoogle Scholar
  86. 86.
    Brown MJ, Dickerson JE. Alpha-blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension. J Hypertens. 1995;13(6):701–7.PubMedCrossRefGoogle Scholar
  87. 87.
    Black HR. Doxazosin as combination therapy for patients with stage 1 and stage 2 hypertension. J Cardiovasc Pharmacol. 2003;41(6):866–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Black HR, Keck M, Meredith P, Bullen K, Quinn S, Koren A. Controlled-release doxazosin as combination therapy in hypertension: the GATES study. J Clin Hypertens. 2006;8(3):159–66. quiz 67-8CrossRefGoogle Scholar
  89. 89.
    Pool JL. Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials. Am Heart J. 1991;122(3 Pt 2):926–31.PubMedCrossRefGoogle Scholar
  90. 90.
    Daae LN, Westlie L. A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk. Blood Press. 1998;7(1):39–45.PubMedCrossRefGoogle Scholar
  91. 91.
    Grimm Jr RH, Flack JM, Grandits GA, Elmer PJ, Neaton JD, Cutler JA, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA. 1996;275(20):1549–56.PubMedCrossRefGoogle Scholar
  92. 92.
    Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. Effects of doxazosin and irbesartan on blood pressure and metabolic control in patients with type 2 diabetes and hypertension. J Cardiovasc Pharmacol. 2005;45(6):599–604.PubMedCrossRefGoogle Scholar
  93. 93.
    Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA. 2000;283(15):1967–75.Google Scholar
  94. 94.
    Chapman N, Chang CL, Dahlof B, Sever PS, Wedel H, Poulter NR, et al. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation. 2008;118(1):42–8.PubMedCrossRefGoogle Scholar
  95. 95.
    Ceral J, Solar M. Doxazosin: safety and efficacy in the treatment of resistant arterial hypertension. Blood Press. 2009;18(1–2):74–7.PubMedCrossRefGoogle Scholar
  96. 96.
    Rodilla E, Costa JA, Perez-Lahiguera F, Baldo E, Gonzalez C, Pascual JM. Spironolactone and doxazosin treatment in patients with resistant hypertension. Rev Esp Cardiol. 2009;62(2):158–66.PubMedCrossRefGoogle Scholar
  97. 97.
    Prichard BN, Gillam PM. Use of propranolol (Inderal) in treatment of hypertension. BMJ. 1964;2(5411):725–7.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol. 2007;100(8):1254–62.PubMedCrossRefGoogle Scholar
  99. 99.
    Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279(23):1903–7.PubMedCrossRefGoogle Scholar
  100. 100.
    Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. Can Med Assoc J. 2006;174(12):1737–42.CrossRefGoogle Scholar
  101. 101.
    Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin. 2010;26(3):615–29.PubMedCrossRefGoogle Scholar
  102. 102.
    Fragasso G, Cera M, Margonato A. Different metabolic effects of selective and nonselective beta-blockers rather than mere heart rate reduction may be the mechanisms by which beta-blockade prevents cardiovascular events. J Am Coll Cardiol. 2009;53(22):2105.PubMedCrossRefGoogle Scholar
  103. 103.
    Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, Jankowski M, Martyniec L, Angielski S, et al. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation. 2003;107(21):2747–52.PubMedCrossRefGoogle Scholar
  104. 104.
    Frishman W. Carvedilol N Engl J Med. 1998;339:1759–65.PubMedCrossRefGoogle Scholar
  105. 105.
    Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292(18):2227–36.PubMedCrossRefGoogle Scholar
  106. 106.
    DiNicolantonio JJ, Hackam DG. Carvedilol: a third-generation beta-blocker should be a first-choice beta-blocker. Exp Rev Cardiovasc Ther. 2012;10(1):13–25.CrossRefGoogle Scholar
  107. 107.
    Marazzi G, Volterrani M, Caminiti G, Iaia L, Cacciotti L, Massaro R, et al. Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients. Adv Ther. 2010;27(9):655–64.PubMedCrossRefGoogle Scholar
  108. 108.
    Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlof B, Poulter NR, et al. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens. 2011;29(10):2004–13.PubMedCrossRefGoogle Scholar
  109. 109.
    Spitalewitz S, Porush JG, Reiser IW. Minoxidil, nadolol, and a diuretic. Once-a-day therapy for resistant hypertension. Arch Int Med. 1986;146(5):882–6.CrossRefGoogle Scholar
  110. 110.
    Leenen FH, Burns RJ, Myers MG, Frankel D. Effects of nifedipine versus hydralazine on sympathetic activity and cardiac function in patients with hypertension persisting on diuretic plus beta-blocker therapy. Cardiovascular drugs and therapy/sponsored by the International Society of Cardiovascular Pharmacotherapy. 1990;4(2):499–504.CrossRefGoogle Scholar
  111. 111.
    Black RN, Hunter SJ, Atkinson AB. Usefulness of the vasodilator minoxidil in resistant hypertension. J Hypertens. 2007;25(5):1102–3.PubMedCrossRefGoogle Scholar
  112. 112.
    Mitchell HC, Graham RM, Pettinger WA. Renal function during long-term treatment of hypertension with minoxidil: comparison of benign and malignant hypertension. Ann Intern Med. 1980;93(5):676–81.PubMedCrossRefGoogle Scholar
  113. 113.
    Spinasse LB, Santos AR, Suffys PN, Muxfeldt ES, Salles GF. Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension. Pharmacogenomics. 2014;15(2):169–78.PubMedCrossRefGoogle Scholar
  114. 114.
    Esler MD, Bohm M, Sievert H, Rump CL, Schmieder RE, Krum H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J. 2014;35(26):1752–9.PubMedCrossRefGoogle Scholar
  115. 115.
    Krum H, Schlaich MP, Sobotka PA, Bohm M, Mahfoud F, Rocha-Singh K, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622–9.PubMedCrossRefGoogle Scholar
  116. 116.
    Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–401.PubMedCrossRefGoogle Scholar
  117. 117.
    Desch S, Okon T, Heinemann D, Kulle K, Rohnert K, Sonnabend M, et al. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension. 2015;65(6):1202–8.PubMedCrossRefGoogle Scholar
  118. 118.
    Mathiassen ON, Vase H, Bech JN, Christensen KL, Buus NH, Schroeder AP, et al. Renal denervation in treatment-resistant essential hypertension. A randomized, SHAM-controlled, double-blinded 24-h blood pressure-based trial. J Hypertens. 2016;34(8):1639–47.PubMedPubMedCentralCrossRefGoogle Scholar
  119. 119.
    Oliveras A, Armario P, Clara A, Sans-Atxer L, Vazquez S, Pascual J, et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. J Hypertens. 2016;34(9):1863–71.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Rosa J, Widimsky P, Waldauf P, Lambert L, Zelinka T, Taborsky M, et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension. 2016;67(2):397–403.PubMedGoogle Scholar
  121. 121.
    • Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet. 2015;385(9981):1957–65. This randomized controlled trial provides evidence for a signifciant BP lowering effect of targeting the sympathetic nervous system via renal denervation in patients with resistant hypertension. PubMedCrossRefGoogle Scholar
  122. 122.
    Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58(7):765–73.PubMedCrossRefGoogle Scholar
  123. 123.
    Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6(4):270–6.PubMedCrossRefGoogle Scholar
  124. 124.
    Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56(15):1254–8.PubMedCrossRefGoogle Scholar
  125. 125.
    Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6(2):152–8.PubMedCrossRefGoogle Scholar
  126. 126.
    Thorp AA, Schlaich MP. Device-based approaches for renal nerve ablation for hypertension and beyond. Front Physiol. 2015;6:193.PubMedPubMedCentralCrossRefGoogle Scholar
  127. 127.
    Victor RG. Carotid baroreflex activation therapy for resistant hypertension. Nat Rev Cardiol. 2015;12(8):451–63.PubMedCrossRefGoogle Scholar
  128. 128.
    Paivanas N, Bisognano JD, Gassler JP. Carotid baroreceptor stimulation and arteriovenous shunts for resistant hypertension. Methodist DeBakey Cardiovasc J. 2015;11(4):223–7.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Hamish CG Prosser
    • 1
  • Cynthia Gregory
    • 1
    • 2
  • Dagmara Hering
    • 1
  • Graham S Hillis
    • 1
    • 2
  • Greg Perry
    • 3
  • Johan Rosman
    • 1
    • 3
  • Carl Schultz
    • 1
    • 2
  • Mark Thomas
    • 3
  • Gerald F Watts
    • 1
    • 2
  • Markus P Schlaich
    • 1
    • 2
    • 3
    • 4
  1. 1.Dobney Hypertension Centre, Faculty of Health and Medical Sciences, School of Medicine-Royal Perth Hospital UnitUniversity of Western AustraliaPerthAustralia
  2. 2.Department of CardiologyRoyal Perth HospitalPerthAustralia
  3. 3.Department of NephrologyRoyal Perth HospitalPerthAustralia
  4. 4.Dobney Chair in Clinical Research, School of Medicine and Pharmacology - Royal Perth Hospital UnitThe University of Western AustraliaPerthAustralia

Personalised recommendations